131 related articles for article (PubMed ID: 35106515)
1. MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression.
Rodriguez BL; Gibbons DL
Cell Rep Med; 2022 Jan; 3(1):100506. PubMed ID: 35106515
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.
Limagne E; Nuttin L; Thibaudin M; Jacquin E; Aucagne R; Bon M; Revy S; Barnestein R; Ballot E; Truntzer C; Derangère V; Fumet JD; Latour C; Rébé C; Bellaye PS; Kaderbhaï CG; Spill A; Collin B; Callanan MB; Lagrange A; Favier L; Coudert B; Arnould L; Ladoire S; Routy B; Joubert P; Ghiringhelli F
Cancer Cell; 2022 Feb; 40(2):136-152.e12. PubMed ID: 35051357
[TBL] [Abstract][Full Text] [Related]
3. Mitophagy: a new actor in the efficacy of chemo-immunotherapy.
Limagne E; Ghiringhelli F
Autophagy; 2022 Dec; 18(12):3033-3034. PubMed ID: 35532360
[TBL] [Abstract][Full Text] [Related]
4. MAPK signaling regulates the efficacy of chemoimmunotherapy.
Ghiringhelli F
Mol Cell Oncol; 2022; 9(1):2054652. PubMed ID: 35529902
[TBL] [Abstract][Full Text] [Related]
5. Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes.
Kanda N; Watanabe S
Endocrinology; 2007 May; 148(5):2317-25. PubMed ID: 17255201
[TBL] [Abstract][Full Text] [Related]
6. A novel CXCL10-based GPI-anchored fusion protein as adjuvant in NK-based tumor therapy.
Muenchmeier N; Boecker S; Bankel L; Hinz L; Rieth N; Lapa C; Mendler AN; Noessner E; Mocikat R; Nelson PJ
PLoS One; 2013; 8(8):e72749. PubMed ID: 24023642
[TBL] [Abstract][Full Text] [Related]
7. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.
Reschke R; Yu J; Flood B; Higgs EF; Hatogai K; Gajewski TF
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593622
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
9. CXCL10 contributes to p38-mediated apoptosis in primary T lymphocytes in vitro.
Sidahmed AM; León AJ; Bosinger SE; Banner D; Danesh A; Cameron MJ; Kelvin DJ
Cytokine; 2012 Aug; 59(2):433-41. PubMed ID: 22652417
[TBL] [Abstract][Full Text] [Related]
10. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4
Hart M; Nickl L; Walch-Rueckheim B; Krammes L; Rheinheimer S; Diener C; Taenzer T; Kehl T; Sester M; Lenhof HP; Keller A; Meese E
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33229509
[TBL] [Abstract][Full Text] [Related]
11. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
12. CXCL10 mediates CD8
Yan W; Qiu L; Yang M; Xu A; Ma M; Yuan Q; Ma X; Liang W; Li X; Lu Y
Cancer Lett; 2023 Jul; 567():216263. PubMed ID: 37354983
[TBL] [Abstract][Full Text] [Related]
13. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.
Dushyanthen S; Teo ZL; Caramia F; Savas P; Mintoff CP; Virassamy B; Henderson MA; Luen SJ; Mansour M; Kershaw MH; Trapani JA; Neeson PJ; Salgado R; McArthur GA; Balko JM; Beavis PA; Darcy PK; Loi S
Nat Commun; 2017 Sep; 8(1):606. PubMed ID: 28928458
[TBL] [Abstract][Full Text] [Related]
14. Dimethylfumarate inhibits CXCL10 via haem oxygenase-1 in airway smooth muscle.
Seidel P; Hostettler KE; Hughes JM; Tamm M; Roth M
Eur Respir J; 2013 Jan; 41(1):195-202. PubMed ID: 22790915
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Smolkin ME; Olson WC; Deacon DH; Smith KT; Galeassi NV; Chianese-Bullock KA; Dengel LT; Marincola FM; Petroni GR; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1189-99. PubMed ID: 27522581
[TBL] [Abstract][Full Text] [Related]
16. MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis.
Deng R; Zhang HL; Huang JH; Cai RZ; Wang Y; Chen YH; Hu BX; Ye ZP; Li ZL; Mai J; Huang Y; Li X; Peng XD; Feng GK; Li JD; Tang J; Zhu XF
Autophagy; 2021 Oct; 17(10):3011-3029. PubMed ID: 33213267
[TBL] [Abstract][Full Text] [Related]
17. Age-related reductions in the activation of mitogen-activated protein kinases p44mapk/ERK1 and p42mapk/ERK2 in human T cells stimulated via ligation of the T cell receptor complex.
Whisler RL; Newhouse YG; Bagenstose SE
Cell Immunol; 1996 Mar; 168(2):201-10. PubMed ID: 8640866
[TBL] [Abstract][Full Text] [Related]
18. Nickel nanoparticles enhance platelet-derived growth factor-induced chemokine expression by mesothelial cells via prolonged mitogen-activated protein kinase activation.
Glista-Baker EE; Taylor AJ; Sayers BC; Thompson EA; Bonner JC
Am J Respir Cell Mol Biol; 2012 Oct; 47(4):552-61. PubMed ID: 22700867
[TBL] [Abstract][Full Text] [Related]
19. EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.
Kapp K; Volz B; Curran MA; Oswald D; Wittig B; Schmidt M
J Immunother Cancer; 2019 Jan; 7(1):5. PubMed ID: 30621769
[TBL] [Abstract][Full Text] [Related]
20. MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.
Yarchoan M; Mohan AA; Dennison L; Vithayathil T; Ruggieri A; Lesinski GB; Armstrong TD; Azad NS; Jaffee EM
PLoS One; 2019; 14(10):e0224600. PubMed ID: 31671149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
